Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/Paraganglioma
NCT05133349Phase 2Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in pheochromocytoma, Paraganglioma (PGL), sponsored by Nanjing First Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT05133349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133349.